Suppr超能文献

接受化疗的儿童甲状腺激素状态的变化。

Changes in thyroid hormone state in children receiving chemotherapy.

作者信息

van Santen H M, Thonissen N M, de Kraker J, Vulsma T

机构信息

Department of Paediatric Endocrinology, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Clin Endocrinol (Oxf). 2005 Feb;62(2):250-7. doi: 10.1111/j.1365-2265.2005.02210.x.

Abstract

OBJECTIVE

The concentrations of thyroid function determinants may change during severe illness. Our goal was to quantify their changes in children with cancer during chemotherapy, and to correlate them to clinical condition and type of drugs.

DESIGN

During a 3-month period all patients admitted for chemotherapy to the paediatric oncology ward were evaluated for inclusion. Patients with brain tumours, neuroblastoma (cranio)spinal irradiation and use of dexamethasone before the first blood sample were excluded.

MEASUREMENTS

Plasma concentrations of T4, T3, rT3, thyroxine-binding globulin (TBG), thyroglobulin (Tg), TSH, IGF-1, cortisol, PRL and physical well-being by means of questionnaires were measured before and during chemotherapy.

RESULTS

In 19 children, 46 courses of chemotherapy and 123 plasma samples were analysed. During chemotherapy, mean concentrations of TSH, T3, Tg and cortisol decreased to 53, 67, 69 and 15% of the baseline value, respectively. Mean plasma rT3 increased to 217% of baseline. In 87% of all courses, one or more thyroid parameter(s) was aberrant. Furthermore, in 23 samples (19%) from 10 patients (53%), the concentration of IGF-1 was below the reference value (adjusted for sex and age). Small changes were seen in scores for clinical condition but none was related to a change in thyroid function determinant. Most changes in thyroid hormones could be attributed to using dexamethasone.

CONCLUSIONS

These results demonstrate that, in children, thyroid hormone state changes significantly during chemotherapy, apparently not related to physical well-being but to the drugs administered. Future investigations should focus on the impact for patient care and possibilities of (preventive) intervention.

摘要

目的

在重症期间,甲状腺功能指标的浓度可能会发生变化。我们的目标是量化癌症患儿化疗期间这些指标的变化,并将其与临床状况和药物类型相关联。

设计

在3个月的时间里,对所有入住儿科肿瘤病房进行化疗的患者进行评估以确定是否纳入研究。排除患有脑肿瘤、神经母细胞瘤(颅)脊髓放疗以及在采集第一份血样前使用地塞米松的患者。

测量

在化疗前和化疗期间,通过问卷测量血浆中T4、T3、反T3(rT3)、甲状腺素结合球蛋白(TBG)、甲状腺球蛋白(Tg)、促甲状腺激素(TSH)、胰岛素样生长因子-1(IGF-1)、皮质醇、催乳素(PRL)的浓度以及身体状况。

结果

对19名儿童的46个化疗疗程和123份血浆样本进行了分析。化疗期间,TSH、T3、Tg和皮质醇的平均浓度分别降至基线值的53%、67%、69%和15%。血浆rT3的平均浓度升至基线值的217%。在所有疗程的87%中,一个或多个甲状腺参数异常。此外,在10名患者(53%)的23份样本(19%)中,IGF-1的浓度低于参考值(根据性别和年龄进行了调整)。临床状况评分有小的变化,但均与甲状腺功能指标的变化无关。甲状腺激素的大多数变化可归因于使用地塞米松。

结论

这些结果表明,在儿童中,化疗期间甲状腺激素状态发生显著变化,显然与身体状况无关,而是与所使用的药物有关。未来的研究应关注对患者护理的影响以及(预防性)干预的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验